First patients recruited into trial of P&G's Asacol

3 December 2007

Cork, Ireland-based biotechnology firm Alimentary Health says that the first patients have been recruited into a clinical study of USA-based Procter & Gamble's Asacol (mesalamine) along with the supplemental Bifidobacterium infantis 35624, the Alimentary Health probiotic technology trademarked by P&G as Bifantis, in the treatment of acute diverticulitis.

Asacol delayed-release tablets are a prescription product indicated in the USA to treat mild-to-moderate flare-ups of ulcerative colitis and maintain remission. Bifantis, a probiotic strain, has been clinically proven to manage all the cardinal symptoms of irritable bowel syndrome in two randomized studies published in Gastroenterology and the American Journal of Gastroenterology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Vaxcyte

A US clinical-stage vaccine company in San Carlos, California, whose 31-valent pneumococcal conjugate vaccine VAX-31 met every primary endpoint of its pivotal adult Phase III trial in October 2026, with a BLA planned for the first half of 2028 and $2.51 billion of cash to get there.

| Headless Content Management with Blaze